石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01093 石药集团

已收盘 05-14 16:09:14

7.960

-0.090

-1.12%

最高8.180	最低7.860	成交量8,177万
今开8.130	昨收8.050	日振幅3.98%
总市值917.15亿	流通市值917.15亿	总股本115.22亿
成交额6.50亿	换手率0.71%	流通股本115.22亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01093","market":"HK","secType":"STK","nameCN":"石药集团","latestPrice":7.96,"timestamp":1778746154001,"preClose":8.05,"halted":0,"volume":81769144,"delay":0,"changeRate":-0.011180124223602575,"floatShares":11522000000,"shares":11522000000,"eps":0.39230254409875615,"marketStatus":"已收盘","change":-0.09,"latestTime":"05-14 16:09:14","open":8.13,"high":8.18,"low":7.86,"amount":650057646,"amplitude":0.039752,"askPrice":7.96,"askSize":1006000,"bidPrice":7.95,"bidSize":66000,"shortable":3,"etf":0,"ttmEps":0.39230254409875615,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778808600000},"marketStatusCode":5,"adr":0,"listingDate":772128000000,"exchange":"SEHK","adjPreClose":8.05,"dividendRate":0.030163,"openAndCloseTimeList":[[1778722200000,1778731200000],[1778734800000,1778745600000]],"volumeRatio":0.95767,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"CSP.HK","impliedVol":0.4899,"impliedVolPercentile":0.2429},"requestUrl":"/m/hq/s/01093/","defaultTab":"news","newsList":[{"id":"2634217641","title":"业绩下滑的石药集团又遇高管离职","url":"https://stock-news.laohu8.com/highlight/detail?id=2634217641","media":"国际金融报","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634217641?lang=zh_cn&edition=full","pubTime":"2026-05-12 21:35","pubTimestamp":1778592900,"startTime":"0","endTime":"0","summary":"5月12日，多家媒体报道称，石药集团执行总裁、全球首席医学官黑永疆于近日正式离职，并在上海开启个人创业。天眼查数据显示，上海慧思博生物医药科技有限公司于2026年4月13日在青浦区成立，法定代表人为黑永疆。这家公司注册资本为500万元，经营范围涵盖技术服务、技术开发、自然科学研究和试验发展、医学研究和试验发展等多个领域，所属行业为科技推广和应用服务业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605123734818918.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605123734818918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1960683339.HKD","LU1993786604.SGD","LU1226287792.SGD","IE00B031HY20.USD","LU0072913022.USD","IE00BZ08YT58.USD","LU0314109678.HKD","LU1226288170.HKD","LU1226288253.USD","LU1813983027.USD","IE00BZ08YR35.GBP","LU1328277881.USD","BK1191","LU0501845795.SGD","IE00BZ08YS42.EUR","HK0000165453.HKD","BK1515","LU0140636845.USD","LU0315179316.USD","IE00B5MMRT66.SGD","LU1226287529.USD","SG9999004220.SGD","IE0008369823.USD","LU0067412154.USD","LU1152091168.USD","01093","LU1008478684.HKD","LU1807302812.USD","LU1226287875.USD","LU1951186391.HKD","LU2039709279.SGD","LU0880133367.SGD","LU0326950275.SGD","IE0008368742.USD","BK1521","IE00B543WZ88.USD","LU1152091754.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634584262","title":"黑永疆离开石药创业，医药老兵“第三阶段”想干什么？","url":"https://stock-news.laohu8.com/highlight/detail?id=2634584262","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634584262?lang=zh_cn&edition=full","pubTime":"2026-05-12 14:10","pubTimestamp":1778566200,"startTime":"0","endTime":"0","summary":"5月6日，工信部刚刚公布了石药集团入选2025年数字化转型典型案例的消息。然而就在几天之后，这艘老牌航母刚刚完成“航母+AI”的华丽转身，正朝着创新药全球化全力调头之际，又一则重磅消息搅动了整个生物医药圈。　　市场消息显示，石药集团执行总裁、全球首席医学官黑永疆博士，已从石药集团正式离职，创立上海慧思博生物医药科技有限公司。　　企业信息显示，慧思博生物成立于2026年4月13日，注册资本500万元，位于上海青浦区。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/2026-05-12/doc-inhxrmyk1526070.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/2026-05-12/doc-inhxrmyk1526070.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00B5MMRT66.SGD","LU0314109678.HKD","SG9999004220.SGD","IE00BZ08YT58.USD","LU1226287875.USD","IE0008368742.USD","BK1161","LU1813983027.USD","BK1574","LU0501845795.SGD","LU1008478684.HKD","LU1152091168.USD","LU2039709279.SGD","LU1807302812.USD","LU1226288253.USD","IE00B543WZ88.USD","LU0880133367.SGD","LU0140636845.USD","LU1226288170.HKD","09939","IE0008369823.USD","LU0326950275.SGD","HK0000165453.HKD","LU1226287792.SGD","LU1328277881.USD","LU1951186391.HKD","LU1993786604.SGD","161022","BK1515","LU0067412154.USD","IE00BZ08YS42.EUR","BK1191","IE00B031HY20.USD","IE00BZ08YR35.GBP","BK1521","LU0072913022.USD","LU1960683339.HKD","LU0315179316.USD","01093","LU1152091754.HKD","159938","LU1226287529.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634402954","title":"石药集团(01093)：SYS 6010于中国再次获纳入突破性治疗品种名单用于治疗局部晚期或转移性食管鳞状细胞癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2634402954","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634402954?lang=zh_cn&edition=full","pubTime":"2026-05-11 17:43","pubTimestamp":1778492619,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团自主研发的SYS 6010近日再次获中国国家药品监督管理局纳入突破性治疗品种名单，拟定适应症为单药用于既往接受含铂化疗及免疫治疗失败的局部晚期或转移性食管鳞状细胞癌患者。此前，该产品针对EGFR突变耐药非小细胞肺癌适应症已于2025年1月获国家药监局纳入突破性治疗品种名单。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石药集团(01093)：SYS 6010于中国再次获纳入突破性治疗品种名单用于治疗局部晚期或转移性食管鳞状细胞癌患者","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","LU0314109678.HKD","SG9999004220.SGD","IE00BZ08YT58.USD","LU1226287875.USD","IE0008368742.USD","LU1813983027.USD","LU0501845795.SGD","LU1008478684.HKD","LU1152091168.USD","LU2039709279.SGD","LU1807302812.USD","LU1226288253.USD","IE00B543WZ88.USD","LU0880133367.SGD","LU0140636845.USD","LU1226288170.HKD","IE0008369823.USD","LU0326950275.SGD","HK0000165453.HKD","LU1226287792.SGD","LU1328277881.USD","LU1951186391.HKD","LU1993786604.SGD","BK1515","LU0067412154.USD","IE00BZ08YS42.EUR","BK1191","IE00B031HY20.USD","IE00BZ08YR35.GBP","BK1521","LU0072913022.USD","LU1960683339.HKD","LU0315179316.USD","01093","LU1152091754.HKD","LU1226287529.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634015154","title":"花旗：中国医疗保健行业基本面持续改善 首选药明康德(02359)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2634015154","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634015154?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:54","pubTimestamp":1778489665,"startTime":"0","endTime":"0","summary":"创新正获得回报，授权交易预付款及里程碑付款带动盈利，创新药销售加速，而CXO订单量更创下历史新高。展望未来，该行预期将有一系列短期催化剂，包括ASCO 2026年数据发布、授权交易势头持续、4月14日药品价格改革后续、CXO指引可能上调，以及市场整合加速利好医疗科技、服务及药房领导者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0307460666.USD","LU0310800965.SGD","LU1226287792.SGD","LU0359202008.SGD","IE00B031HY20.USD","LU1242518857.USD","LU2360032135.SGD","IE00BZ08YT58.USD","LU0314109678.HKD","LU1226288253.USD","LU0516423174.USD","LU1506573853.SGD","LU1366192091.USD","BK1191","LU2488822045.USD","LU2097828714.EUR","LU0979878070.USD","BK1515","LU0072461881.USD","LU0980610538.SGD","LU0315179316.USD","IE00B5MMRT66.SGD","LU2242644610.SGD","LU0572944931.SGD","LU1997245177.USD","SG9999004220.SGD","IE0008369823.USD","LU2125154935.USD","LU1719994722.HKD","BK1141","LU0516422366.SGD","01093","02359","LU1008478684.HKD","01276","603259","LU1951186391.HKD","LU2417539215.USD","01801","LU1023057109.AUD","LU0455707207.USD","LU1997244956.HKD","01672","LU2045819591.USD","LU0098860793.USD","BK4504","LU0170899867.USD","LU0326950275.SGD","02269","LU0203347892.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161450093","title":"石药集团2026年4月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1161450093","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161450093?lang=zh_cn&edition=full","pubTime":"2026-05-04 17:17","pubTimestamp":1777886241,"startTime":"0","endTime":"0","summary":"2026年5月4日，石药集团有限公司（股票代码：01093）披露2026年4月股份变动月报表，报告期截至2026年4月30日。根据公告显示，报告期内公司法定及注册股本未发生变化，期末已发行普通股股数为11,522,451,732股，库存股份数目为0，期间无新增发行、回购或注销股本活动。\n在股份期权方面，根据公司于2015年12月9日生效的2015年购股权计划，截至4月末的股份期权总数为1,300,000股，本月内无新股发行或库存股转让，期末持有的股份期权数量与上月份相同。公司重申，当前公众持股量符合香港联交所上市规则要求。本次月报由公司秘书罗泰安签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631229636","title":"汇添富基金增持石药集团(01093)296.6万股 每股作价约8.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2631229636","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631229636?lang=zh_cn&edition=full","pubTime":"2026-04-30 19:10","pubTimestamp":1777547452,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，4月28日，汇添富基金管理股份有限公司增持石药集团(01093)296.6万股，每股作价8.4977港元，总金额约为2520.42万港元。增持后最新持股数目约为5.79亿股，持股比例为5.02%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2039709279.SGD","LU0314109678.HKD","LU0315179316.USD","LU1993786604.SGD","LU1226288253.USD","LU0072913022.USD","IE00BZ08YR35.GBP","IE00B5MMRT66.SGD","LU1152091168.USD","LU1960683339.HKD","IE00B543WZ88.USD","LU0880133367.SGD","LU1951186391.HKD","BK1521","LU1226287529.USD","LU1226288170.HKD","IE00BZ08YS42.EUR","BK1191","LU1328277881.USD","BK1515","LU0067412154.USD","LU1226287792.SGD","HK0000165453.HKD","EWH","IE0008368742.USD","SG9999004220.SGD","IE00BZ08YT58.USD","LU0140636845.USD","IE0008369823.USD","LU0501845795.SGD","01093","LU1152091754.HKD","IE00B031HY20.USD","LU1807302812.USD","LU1008478684.HKD","LU1813983027.USD","LU0326950275.SGD","LU1226287875.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631799055","title":"石药集团一项创新研究成果在ACS Org. Process Res. Dev.发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2631799055","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631799055?lang=zh_cn&edition=full","pubTime":"2026-04-30 08:47","pubTimestamp":1777510064,"startTime":"0","endTime":"0","summary":"【石药集团一项创新研究成果在ACS Org. Process Res. Dev.发表】据石药集团消息，近日，由石药集团研发的基于在线红外光谱技术用于寡核苷酸固相合成脱保护工艺优化的研究成果以研究论文（Article）形式发表在国际著名化学期刊ACS旗下Org. Process Res. Dev.杂志。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604303725558663.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604303725558663.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","LU2039709279.SGD","LU1993786604.SGD","01093","IE00BZ08YR35.GBP","LU1226288170.HKD","SG9999004220.SGD","BK1521","LU0140636845.USD","LU1226287875.USD","LU1807302812.USD","LU0501845795.SGD","LU0880133367.SGD","IE00BZ08YT58.USD","IE00B5MMRT66.SGD","LU1226288253.USD","LU0314109678.HKD","IE00B031HY20.USD","LU1226287792.SGD","LU1328277881.USD","LU1008478684.HKD","IE0008369823.USD","IE00B543WZ88.USD","LU0326950275.SGD","LU0072913022.USD","LU1960683339.HKD","HK0000165453.HKD","LU0315179316.USD","IE0008368742.USD","IE00BZ08YS42.EUR","LU0067412154.USD","LU1813983027.USD","LU1152091168.USD","LU1226287529.USD","LU1152091754.HKD","LU1951186391.HKD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631518822","title":"石药集团(01093)：注射用两性霉素B脂质体(HC1507G2) 在欧洲获上市申请批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2631518822","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631518822?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:05","pubTimestamp":1777460747,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，本集团自主开发的注射用两性霉素B脂质体(该产品)在欧盟的上市申请已获批准。两性霉素B是大环多烯类抗真菌抗生素，通过与真菌细胞膜上的甾醇结合，改变细胞膜通透性，发挥抗真菌作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436407.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","LU1813983027.USD","IE00BZ08YT58.USD","LU1152091754.HKD","IE00B5MMRT66.SGD","LU1226288253.USD","HK0000165453.HKD","IE00BZ08YS42.EUR","LU0067412154.USD","BK1515","LU1226287875.USD","LU0880133367.SGD","IE00B031HY20.USD","IE00BZ08YR35.GBP","LU0326950275.SGD","LU1807302812.USD","LU1328277881.USD","LU1226287792.SGD","LU0314109678.HKD","LU1960683339.HKD","LU1993786604.SGD","LU1951186391.HKD","01093","SG9999004220.SGD","IE0008368742.USD","LU1226288170.HKD","LU2039709279.SGD","IE0008369823.USD","LU0315179316.USD","LU1008478684.HKD","LU0140636845.USD","LU0072913022.USD","BK1191","LU1152091168.USD","LU0501845795.SGD","BK1521","LU1226287529.USD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631590776","title":"石药集团(01093)开发的抗体偶联药物SYS6051在美国获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2631590776","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631590776?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:02","pubTimestamp":1777460576,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团(01093)公布，该集团开发的抗体偶联药物SYS6051的试验性新药(IND)申请已获美国食品药品监督管理局(FDA)批准，可在美国开展临床试验。该产品亦已于2026年4月获得中华人民共和国国家药品监督管理局批准，可以在中国开展临床试验。该产品为一款靶向人组织因子(TF)的抗体偶联药物，可与肿瘤细胞表面的组织因子结合，通过内吞作用进入细胞并释放毒素，达到杀伤肿瘤细胞的作用。本次获批的适应症为晚期实体瘤。临床前研究显示，该产品对多种癌症均有较好的抗肿瘤作用，有望在后续临床试验中展现出良好的治疗效果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436402.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石药集团(01093)开发的抗体偶联药物SYS6051在美国获临床试验批准","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1960683339.HKD","IE00B031HY20.USD","LU1226287529.USD","IE00BZ08YS42.EUR","LU1152091754.HKD","IE00B543WZ88.USD","LU1951186391.HKD","LU1008478684.HKD","LU0072913022.USD","IE00BZ08YR35.GBP","IE00B5MMRT66.SGD","HK0000165453.HKD","LU1152091168.USD","LU0501845795.SGD","LU1226287792.SGD","LU1807302812.USD","LU0315179316.USD","LU0326950275.SGD","IE0008369823.USD","LU2039709279.SGD","IE0008368742.USD","01093","LU1226287875.USD","BK1191","LU0314109678.HKD","LU1226288253.USD","BK1515","SG9999004220.SGD","LU1226288170.HKD","LU0067412154.USD","LU0880133367.SGD","BK1521","LU1328277881.USD","LU1813983027.USD","LU1993786604.SGD","IE00BZ08YT58.USD","LU0140636845.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101195654","title":"石药集团拟回购不超过已发行股份10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1101195654","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101195654?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:43","pubTimestamp":1777376603,"startTime":"0","endTime":"0","summary":"石药集团于4月29日公告，董事会拟于2026年5月28日召开的股东周年大会上提请授予回购公司股份的一般性授权，最高回购规模不超过公司于该决议案通过当日已发行股份总数的10%。根据公告，石药集团当前已发行股份数为11,522,451,732股，此次购回权限上限对应约1,152,245,173股。此外，石药集团拟在同日举行的股东周年大会上提议续聘核数师，并就年度财务报表、董事薪酬等事项作出决议。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石药集团拟回购不超过已发行股份10%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191267081","title":"石药集团2025年收入下滑10.4%至260.06亿元，净利同比降10.3%并聚焦创新药布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1191267081","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191267081?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:39","pubTimestamp":1777376372,"startTime":"0","endTime":"0","summary":"石药集团在其2025年度报告中披露，期内实现总收入人民币260.06亿元，较2024年的290.09亿元下降10.4%。按业务板块划分，成药业务收入为人民币205.84亿元，同比下降13.3%；原料产品业务收入36.57亿元，同比增长2.1%；功能食品及其他业务收入17.65亿元，同比增长4.5%。利润方面，股东应占溢利约人民币38.82亿元，较上年度43.28亿元下降10.3%。从财务结构来看，截至2025年12月31日，集团总资产为约人民币466.98亿元，较上年增长约5.2%；流动比率为2.21倍，总体偿债能力良好。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"石药集团2025年收入下滑10.4%至260.06亿元，净利同比降10.3%并聚焦创新药布局","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630478320","title":"港股石药集团午后跌近4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630478320","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630478320?lang=zh_cn&edition=full","pubTime":"2026-04-28 15:00","pubTimestamp":1777359613,"startTime":"0","endTime":"0","summary":"4月28日，石药集团(01093.HK)午后跌近4%，截至发稿跌4.88%，报8.38港元，成交额6.68亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604283722140067.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604283722140067.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1152091168.USD","LU1807302812.USD","LU1152091754.HKD","LU0067412154.USD","LU1328277881.USD","LU0140636845.USD","LU1226287875.USD","VXUS","IE0008368742.USD","IE00B543WZ88.USD","LU0501845795.SGD","LU1008478684.HKD","HK0000165453.HKD","IE00BZ08YT58.USD","01093","LU1226287529.USD","IE00B031HY20.USD","IE00BZ08YS42.EUR","BK1191","LU0880133367.SGD","LU1226288253.USD","LU1960683339.HKD","SG9999004220.SGD","LU2039709279.SGD","LU1993786604.SGD","LU0315179316.USD","BK4588","LU0314109678.HKD","LU0072913022.USD","LU1226287792.SGD","LU0326950275.SGD","BK1515","LU1226288170.HKD","IE00B5MMRT66.SGD","IE00BZ08YR35.GBP","LU1813983027.USD","BK1521","IE0008369823.USD","LU1951186391.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119737549","title":"异动解读 | 石药集团盘中大跌5.11%，附属公司一季度亏损同比扩大近249%拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1119737549","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119737549?lang=zh_cn&edition=full","pubTime":"2026-04-28 14:39","pubTimestamp":1777358385,"startTime":"0","endTime":"0","summary":"石药集团今日盘中股价大幅下跌5.11%，引发了市场关注。消息面上，此次下跌主要受到其附属公司石药创新披露的一季度业绩影响。数据显示，石药创新一季度虽然营业收入同比增长40.82%，达到6.65亿元，但归属于上市公司股东的净亏损却同比大幅扩大248.88%，达到9385.47万元；扣除非经常性损益后的净利润为-1.11亿元，同比下降262.55%。此前，交银国际维持对石药集团的“中性”评级，目标价为8.7港元。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149449287","title":"石药集团2026年第一季度营收6.65亿元，经调整净利润-1.11亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1149449287","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149449287?lang=zh_cn&edition=full","pubTime":"2026-04-27 20:12","pubTimestamp":1777291923,"startTime":"0","endTime":"0","summary":"本季度信息\n石药集团于2026年第一季度实现营业收入6.65亿元，同比增长40.82%。经扣除非经常性损益后，公司净利润为-1.11亿元，同比下降262.55%。同期经营活动产生的现金流量净额为-1.80亿元，同比下降106.82%。在成本结构方面，管理费用同比增长56.88%，研发费用同比增长13.64%。\n业务分项\n公告显示，功能性原料及生物制药产品营收增长显著，成为收入上扬的主要动力之一；同期巨石生物因SYS6002项目对外授权合作达到研发里程碑节点，确认了1,000万美元收入，对整体业绩亦形成一定贡献。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630773396","title":"石药集团(01093)：石药创新一季度归母净亏损9385.47万元，同比扩大248.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630773396","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630773396?lang=zh_cn&edition=full","pubTime":"2026-04-27 20:06","pubTimestamp":1777291602,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团(01093)发布公告，公司附属公司石药创新制药股份有限公司(石药创新)于2026年第一季度取得营业收入6.65亿元，同比增长40.82%;归属于上市公司股东的净亏损9385.47万元，同比扩大248.88%;基本每股亏损0.0674元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434659.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"石药集团(01093)：石药创新一季度归母净亏损9385.47万元，同比扩大248.88%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1951186391.HKD","LU0067412154.USD","LU0315179316.USD","LU2039709279.SGD","IE0008369823.USD","LU0314109678.HKD","LU0326950275.SGD","LU1226287875.USD","LU1328277881.USD","LU1960683339.HKD","LU1993786604.SGD","SG9999004220.SGD","BK1515","LU0140636845.USD","IE00BZ08YR35.GBP","LU0501845795.SGD","LU0072913022.USD","BK1521","LU1152091168.USD","LU1152091754.HKD","LU0880133367.SGD","IE00B031HY20.USD","LU1226287529.USD","LU1226287792.SGD","LU1807302812.USD","BK1191","01093","LU1226288170.HKD","IE0008368742.USD","IE00BZ08YS42.EUR","IE00B543WZ88.USD","LU1813983027.USD","LU1008478684.HKD","IE00B5MMRT66.SGD","LU1226288253.USD","HK0000165453.HKD","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629684540","title":"石药集团(01093)：高选择性KAT 6抑制剂(SYH2095片)在美国获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2629684540","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629684540?lang=zh_cn&edition=full","pubTime":"2026-04-24 19:39","pubTimestamp":1777030777,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团与杭州英创医药科技有限公司合作开发的化学1类新药SYH2095片已获得美国食品药品监督管理局批准，可在美国开展临床试验。该产品是一种新型的高选择性赖氨酸乙酰转移酶6抑制剂，属于一类表观遗传抗癌药。临床前研究表明，该产品对KAT 6显示出高效且具选择性的抑制作用，可显着抑制肿瘤生长，并具备良好的药代动力学特性与安全性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433614.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1521","LU0314109678.HKD","IE00BZ08YT58.USD","LU0067412154.USD","IE00B031HY20.USD","LU1960683339.HKD","IE0008369823.USD","BK1515","IE00B5MMRT66.SGD","LU1813983027.USD","LU0315179316.USD","IE0008368742.USD","IE00BZ08YS42.EUR","BK1191","01093","LU1226287875.USD","KAT","LU0880133367.SGD","SG9999004220.SGD","LU1152091168.USD","HK0000165453.HKD","LU1226288170.HKD","LU1226287529.USD","LU2039709279.SGD","LU0072913022.USD","LU1008478684.HKD","LU1993786604.SGD","LU1328277881.USD","LU1807302812.USD","LU0501845795.SGD","IE00B543WZ88.USD","LU1226288253.USD","IE00BZ08YR35.GBP","LU1951186391.HKD","LU0140636845.USD","LU1226287792.SGD","LU1152091754.HKD","LU0326950275.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629772986","title":"智通港股早知道 | 宁德时代(03750)股东询价转让A股定价为410.34元/股 氮肥价格可能进一步上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2629772986","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629772986?lang=zh_cn&edition=full","pubTime":"2026-04-21 07:28","pubTimestamp":1776727718,"startTime":"0","endTime":"0","summary":"根据2026年4月20日询价申购情况，初步确定的本次询价转让价格为410.34元/股。本次询价转让不通过集中竞价交易方式或大宗交易方式进行，不属于通过二级市场减持。受让方通过询价转让受让的股份，在受让后6个月内不得转让。截至收盘，暗盘交易显示报价333港元，较招股价209.88港元上涨58.66%，每手100股，不计手续费，每手赚12312港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"bd99c7d8869305150ea2122170bfd90e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2125910500.SGD","LU1152091168.USD","LU1008478684.HKD","LU0132412106.USD","LU0449509016.USD","LU0106252389.USD","02691","IE0003851619.USD","SHPMY","IE0003795394.USD","LU0543330483.HKD","LU1807302812.USD","LU0823426308.USD","LU2357125470.USD","IE00B5MMRT66.SGD","LU0164865239.USD","LU2097828714.EUR","BK0224","LU1226287529.USD","LU1242518931.SGD","LU2039709279.SGD","LU1188198961.HKD","LU0531970944.HKD","LU1226287792.SGD","LU1794554557.SGD","LU0405327148.USD","LU2153592121.USD","LU0516423174.USD","LU2424517915.HKD","LU0327786744.USD","BK4526","LU2476274308.USD","LU0823414478.USD","LU0326950275.SGD","LU0320764755.SGD","LU0149534421.HKD","LU2298322129.HKD","LU2360107325.USD","EVS.SI","LU0315179316.USD","LU2298321311.HKD","SG9999000459.SGD","LU0106959298.USD","LU1997244956.HKD","IE00BZ08YR35.GBP","LU2328871848.SGD","LU1039395188.USD","IE00B031HY20.USD","IE0008368742.USD","LU1655091616.SGD","SG9999002828.SGD","LU0672654166.SGD","LU0043850808.USD","LU1868838027.USD","301200","BK1129","LU2238339852.HKD","LU2242644610.SGD","LU2125910849.SGD","LU0029875118.USD","LU0823414551.USD","SG9999004220.SGD","LU1813983027.USD","06608","LU0611395673.USD","LU0165289439.USD","LU1934453819.USD","LU1048588211.SGD","01093","000756","BK1191","LU0328353924.USD","LU0651946864.USD","LU1769817096.USD","LU2045819591.USD","LU0048580855.USD","LU1226288253.USD","IE00BPRC5H50.USD","LU2152927971.USD","03393","LU2092937221.SGD","BK4588","LU0605514214.HKD","BK1521","LU0607220059.USD","04335","LU0469268626.HKD","LU0650527681.SGD","LU0821914370.USD","LU1048596156.SGD","LU1226287875.USD","LU1979443071.USD","IE00BZ08YS42.EUR","LU1251922891.USD","LU0326948709.USD","LU1303224171.USD","LU0047713382.USD","LU2097828805.USD","LU0302445910.USD","LU1146622755.USD","LU0405327494.USD","LU0107464264.USD","LU2506952337.HKD","LU2298064838.USD","LU2153591404.USD","CBLUY","LU0516422440.USD","LU0823426480.USD","IE00BZ199S13.USD","00719","HK0000165453.HKD","LU0359201885.HKD","LU0502904849.HKD","LU2249611893.SGD","INTC","LU0516422952.EUR","BK4141","IE00B8L5B284.USD","02607","LU0269904917.USD","LU0516423091.SGD","LU0828237940.HKD","LU1960683339.HKD","SG9999000327.SGD","SG9999001689.USD","BK1154","IE00B543WZ88.USD","LU1951186391.HKD","LU0501845795.SGD","LU2580892862.HKD","LU0214875030.USD","LU2476274720.SGD","LU0051755006.USD","LU0231483743.USD","LU0049853897.USD","LU2477742899.HKD","01866","LU1820825898.SGD","02575","603093","LU0314109678.HKD","600941","00451","02476","LU0509642566.USD","LU1997245177.USD","LU0143863198.USD","LU0188438112.USD","SGXZ81163826.USD","LU0228659784.USD","LU1993786604.SGD","LU1023057109.AUD","LU1868837565.USD","LU0106259558.USD","LU0594300419.USD","LU2097828557.USD","LU0828238088.HKD","00941","LU0572944931.SGD","LU0011963245.USD","LU0261950470.USD","PLUG","LU1861214812.USD","LU1880383440.USD","IE0032431581.USD","LU1328277881.USD","LU0449515922.USD","LU2399975544.HKD","IE00B29SXG58.USD","BK4519","LU0048575426.USD","LU0067412154.USD","BK1515","LU0828237510.HKD","LU0054450605.USD","LU0140636845.USD","LU0880133367.SGD","HK0000181112.HKD","LU1064130708.USD","LU2394011477.USD","IE00BZ08YT58.USD","BK1554","LU2449936058.SGD","LU0370786039.SGD","COIN","09696","IE00B3M56506.USD","LU0359202008.SGD","LU0531971595.HKD","LU0593848301.USD","LU0871576103.HKD","SG9999002463.SGD","BK1610","LU2041044095.USD","LU1969619763.USD","META","300750","LU2495084118.USD","LU0039217434.USD","LU1978683503.SGD","LU2294711713.HKD","LU2580892789.USD","TSLA","LU1051768304.USD","SG9999001903.USD","LU1515016050.SGD","LU1719994722.HKD","LU2097828631.EUR","IE00BD6J9T35.USD","LU1152091754.HKD","LU0455707207.USD","LU2289578879.USD","LU2348774022.SGD","LU1997245094.SGD","LU2506952253.HKD","SG9999001846.SGD","LU0456827905.SGD","LU0463099449.HKD","LU1880383366.USD","BK1147","LU1102505762.USD","LU1226288170.HKD","LU0594300179.USD","LU1770034418.SGD","SNFRY","LU1051769294.HKD","LU0048388663.USD","LU1939255532.USD","BK1594","LU1580142542.USD","LU2275660780.HKD","00297","03200","LU0251143458.SGD","LU0505663152.USD","LU0143863784.USD","IE0008369823.USD","LU1242518857.USD","LU1781817850.SGD","LU2294711473.HKD","601607","LU1255011170.USD","LU0259732245.USD","SGXZ49509284.SGD","BK1116","LU2506952410.USD","002466","LU0823437842.USD","LU0164872284.USD","300476","LU0348805143.USD","LU0359201612.USD","LU0651947912.USD","LU0312595415.SGD","SG9999003461.SGD","LU0210526637.USD","BK4585","LU0979878070.USD","LU1721428347.USD","LU0124384867.USD","LU1720050803.USD","LU0072913022.USD","LU0254981946.USD","LU0128522157.USD","LU1961090484.USD","03750","LU1831875114.USD","LU0072462343.USD","LU0516422366.SGD","LU0244354667.USD","LU0724618433.USD","HK0000181138.USD","LU1064131003.USD","LU2360108059.USD","LU1102505929.USD","LU1861219969.SGD","LU2097828474.EUR","LU2506951792.HKD","LU2348773727.SGD","LU1808992512.USD","LU2148510915.USD","LU0181495838.USD","03983","LU1769817179.HKD","LU2778985437.USD","LU0235996351.USD","SG9999014674.SGD","LU0192582467.USD","LU3063872942.SGD","IE00B8HQ1Z84.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628749960","title":"石药集团(01093)：注射用西罗莫司(白蛋白结合型)(HB1901)用于治疗晚期恶性血管周围上皮样细胞瘤(PEComa)的Ib / III期临床研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2628749960","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628749960?lang=zh_cn&edition=full","pubTime":"2026-04-20 17:51","pubTimestamp":1776678667,"startTime":"0","endTime":"0","summary":"HB1901表现出优异疗效，有望填补国内该适应症治疗空白，成为国内晚期恶性PEComa首款标准治疗方案。约50 %的恶性PEComa患者确诊时已属晚期，此时常合并转移，预后差。HB1901 -004是一项旨在评价注射用西罗莫司在晚期恶性PEComa患者中安全性与有效性的Ib / III期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","LU0315179316.USD","IE0008369823.USD","LU1226287875.USD","IE00BZ08YT58.USD","LU0072913022.USD","LU1152091754.HKD","LU1807302812.USD","LU1226287529.USD","LU1951186391.HKD","01093","BK1521","LU0067412154.USD","LU0140636845.USD","LU1226287792.SGD","BK1191","IE00BZ08YS42.EUR","IE00B543WZ88.USD","LU0501845795.SGD","LU1008478684.HKD","LU1960683339.HKD","LU2039709279.SGD","SG9999004220.SGD","LU1328277881.USD","IE0008368742.USD","LU0314109678.HKD","BK1515","LU0326950275.SGD","IE00BZ08YR35.GBP","LU1226288170.HKD","LU1813983027.USD","HK0000165453.HKD","BK4134","IE00B031HY20.USD","LU1993786604.SGD","LU1152091168.USD","LU0880133367.SGD","III","LU1226288253.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628749339","title":"中国“药二代”答卷","url":"https://stock-news.laohu8.com/highlight/detail?id=2628749339","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628749339?lang=zh_cn&edition=full","pubTime":"2026-04-20 17:47","pubTimestamp":1776678462,"startTime":"0","endTime":"0","summary":"文｜锦缎2026年3月26日，港股上市药企中国生物制药交出了一份不错的年度答卷：全年实现营收318.3亿元，同比增长10.3%；经调整归母净利润45.4亿元，同比增长31.4%。姐妹俩临危受命，开启了葵花药业的“二代”接班之路。其中，最具代表性的便是石药集团的蔡磊。中国生物制药的谢家姐弟，无疑是意气风发的典型代表。2015年，身为泰国正大集团第四代、年仅23岁的谢其润正式接任中国生物制药董事会主席。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1776396457634211965","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU1951186391.HKD","LU0067412154.USD","LU0315179316.USD","LU2039709279.SGD","IE0008369823.USD","LU0314109678.HKD","LU0326950275.SGD","LU1226287875.USD","LU1328277881.USD","LU1960683339.HKD","LU1993786604.SGD","SG9999004220.SGD","BK1515","LU0140636845.USD","IE00BZ08YR35.GBP","LU0501845795.SGD","LU0072913022.USD","BK1521","LU1152091168.USD","LU1152091754.HKD","LU0880133367.SGD","IE00B031HY20.USD","LU1226287529.USD","LU1226287792.SGD","LU1807302812.USD","BK1191","01093","LU1226288170.HKD","IE0008368742.USD","IE00BZ08YS42.EUR","IE00B543WZ88.USD","LU1813983027.USD","LU1008478684.HKD","IE00B5MMRT66.SGD","LU1226288253.USD","HK0000165453.HKD","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150356709","title":"异动解读 | 石药集团盘中大跌5.03%，市场消化新药获批利好预期后回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1150356709","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150356709?lang=zh_cn&edition=full","pubTime":"2026-04-17 11:25","pubTimestamp":1776396328,"startTime":"0","endTime":"0","summary":"石药集团今日盘中股价大跌5.03%，引起了市场关注。消息面上，石药集团自主研发的靶向人组织因子（TF）抗体偶联药物SYS6051已获国家药品监督管理局批准，可在中国开展晚期实体瘤临床试验。该产品按治疗用生物制品1类申报，临床前研究显示其对多种癌症具有较好的抗肿瘤作用。由于该利好消息此前已发布，市场或已提前消化相关预期，导致股价今日出现回调。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cspc.com.hk","stockEarnings":[{"period":"1week","weight":-0.0231},{"period":"1month","weight":-0.1056},{"period":"3month","weight":-0.2061},{"period":"6month","weight":0.0139},{"period":"1year","weight":0.4971},{"period":"ytd","weight":-0.0451}],"compareEarnings":[{"period":"1week","weight":0.0067},{"period":"1month","weight":0.0284},{"period":"3month","weight":-0.0238},{"period":"6month","weight":-0.0253},{"period":"1year","weight":0.1419},{"period":"ytd","weight":0.0296}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石药集团有限公司是一家主要从事药品生产和销售的投资控股公司。该公司以“石药”品牌销售其产品。该公司包括四个业务部门：成药部门、抗生素（中间体及原料药）部门、维生素C（原料药）部门及咖啡因及其他（原料药）部门，分别从事生产及销售相关药品业务。该公司的成药包括抗生素、心脑血管用药、糖尿病用药、精神神经用药、抗肿瘤用药及中医药产品。该公司还通过其子公司从事提供药品研发服务及污水及药物副产品处理业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.009625},{"month":2,"riseRate":0.75,"avgChangeRate":0.094687},{"month":3,"riseRate":0.46875,"avgChangeRate":0.017323},{"month":4,"riseRate":0.59375,"avgChangeRate":0.057765},{"month":5,"riseRate":0.59375,"avgChangeRate":0.044614},{"month":6,"riseRate":0.322581,"avgChangeRate":0.003636},{"month":7,"riseRate":0.375,"avgChangeRate":0.009082},{"month":8,"riseRate":0.4375,"avgChangeRate":0.010009},{"month":9,"riseRate":0.5,"avgChangeRate":0.000153},{"month":10,"riseRate":0.5625,"avgChangeRate":0.010484},{"month":11,"riseRate":0.46875,"avgChangeRate":0.00638},{"month":12,"riseRate":0.5,"avgChangeRate":-0.013271}],"exchange":"SEHK","name":"石药集团","nameEN":"CSPC PHARMA"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石药集团,01093,石药集团股票,石药集团股票老虎,石药集团股票老虎国际,石药集团行情,石药集团股票行情,石药集团股价,石药集团股市,石药集团股票价格,石药集团股票交易,石药集团股票购买,石药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}